Our Milestones
In 2001, ev3 was founded with a single mission: to elevate and transform endovascular treatment. Today, that vital mission is embodied in our vision:
Be the best at identifying and treating peripheral arterial and neurovascular disease, leading with breakthrough technologies and processes.
- Feb01
ev3 Inc. Founded - Jun01
MicroVena Acquired - Jan02
MitraLife Acquired
MTI Distribution Agreement
European Commercial Operations Launched - Mar02
EndiCOR Acquired - Aug02
Appriva Medical Acquired - Oct02
Dendron Acquired - Nov02
Intra-Therapeutics Acquired
- Feb03
Japan Commercial Operations Launched - Sep03
ev3 and MTI Affiliated Through Common Ownership - Jun05
IPO - Jan06
ev3 Completes Acquistion of Public Minority Stake in MTI - Oct07
ev3 and FoxHollow Merge - Jun09
Chestnut Medical Acquired
From our inception forward, we have diligently brought next-generation, clinically-proven therapies to the world. This achievement is made possible by the talent and motivation of our employees, a commitment to rapid innovation, a global perspective—and a personal touch. We take tremendous pride in our history, and it is with great enthusiasm that we invite you to
take part in the continued transformation of our future.
Print
